Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024)

Avalo Therapeutics' Receivables - Other history spans 9 years, with the latest figure at -$600000.0 for Q4 2024.

  • For Q4 2024, Receivables - Other fell 20.0% year-over-year to -$600000.0; the TTM value through Dec 2024 reached -$600000.0, down 20.0%, while the annual FY2024 figure was $611000.0, 222.2% up from the prior year.
  • Receivables - Other reached -$600000.0 in Q4 2024 per AVTX's latest filing, up from -$900000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $4.3 million in Q3 2020 to a low of -$900000.0 in Q3 2024.
  • Average Receivables - Other over 5 years is $1.3 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Receivables - Other: skyrocketed 1958.27% in 2020, then crashed 158.52% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $2.2 million in 2020, then surged by 69.34% to $3.7 million in 2021, then crashed by 48.68% to $1.9 million in 2022, then crashed by 126.06% to -$500000.0 in 2023, then decreased by 20.0% to -$600000.0 in 2024.
  • Per Business Quant, the three most recent readings for AVTX's Receivables - Other are -$600000.0 (Q4 2024), -$900000.0 (Q3 2024), and $33000.0 (Q2 2024).